Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

Gynecologic Oncology

Volumn 121, Issue 2, 2011, Pages 353-357

  Zhang, Shiyu ^a   Royer, Robert ^a   Li, Song ^a   McLaughlin, John R ^b   Rosen, Barry ^a   Risch, Harvey A ^c   Fan, Isabel ^b   Bradley, Linda ^b   Shaw, Patricia A ^a   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; FEMALE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; GERM LINE; GROUPS BY AGE; HUMAN; ITALY; JEW; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; OVARY CANCER; PAKISTAN; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; ONTARIO; OVARIAN NEOPLASMS; PREVALENCE; YOUNG ADULT;

EID: 79955478110     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.01.020     Document Type: Article

References (24)

1. S.A. Narod, D. Ford, P. Devilee, R.B. Barkardottir, J. Eyfjord, G. Lenoir, O. Serova, D. Easton, and D. Goldgar Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium Am. J. Hum. Genet. 57 1995 957 958
2. H.A. Risch, J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P.A. Shaw, and S.A. Narod Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J. Natl Cancer Inst. 98 2006 1694 1706 (Pubitemid 44942707)
3. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, H. Arango, J. LaPolla, M. Hoffman, M.A. Martino, K. Wakeley, G. Wilbanks, and S. Nicosia BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816 (Pubitemid 41798292)
4. F.B. Hogervorst, P.M. Nederlof, J.J. Gille, C.J. McElgunn, M. Grippeling, R. Pruntel, R. Regnerus, T. van Welsem, R. van Spaendonk, F.H. Menko, I. Kluijt, and C. Dommering Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method Cancer Res. 63 2003 1449 1453 (Pubitemid 36373627)
5. M.A. Unger, K.L. Nathanson, K. Calzone, D. Antin-Ozerkis, H.A. Shih, A.M. Martin, G.M. Lenoir, S. Mazoyer, and B.L. Weber Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing Am. J. Hum. Genet. 67 2000 841 850
6. R. Moslehi, W. Chu, B. Karlan, D. Fishman, H. Risch, A. Fields, D. Smotkin, Y. Ben-David, J. Rosenblatt, D. Russo, P. Schwartz, and N. Tung BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer Am. J. Hum. Genet. 66 2000 1259 1272 (Pubitemid 30468783)
7. P.N. Tonin, A.-M. Mes-Masson, S.A. Narod, P. Ghadirian, and D. Provencher Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history Clin. Genet. 55 1999 318 324 (Pubitemid 29295324)
8. G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi, and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes Clin. Genet. 57 2000 213 220 (Pubitemid 30168749)
9. BRCA1 Exon 13 Duplication Screening Group The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations Am. J. Hum. Genet. 67 2000 207 212
10. S. Zhang, G. Kuperstein, and S.A. Narod Mutation screening using fluorescence multiplex denaturing gradient gel electrophoresis (FMD): detecting mutations in the BRCA1 gene Nat. Protoc. 1 2007 3101 3110
11. E. Gross, N. Arnold, K. Pfeifer, K. Bandick, and M. Kiechle Identification of specific BRCA1 and BRCA2 variants by DHPLC Hum. Mutat. 16 2000 345 353
12. S. Agata, M. Dalla Palma, M. Callegaro, M.C. Scaini, C. Menin, C. Ghiotto, O. Nicoletto, G. Zavagno, L. Chieco-Bianchi, E. D'Andrea, and M. Montagna Large genomic deletions inactivate the BRCA2 gene in breast cancer families J. Med. Genet. 42 2005 e64
13. Breast Cancer Information Core (BIC). Available at: http://www.nhgri.nih. gov/Intramural-research/Lab-transfer/Bic/.
14. J. Lubinski, C.M. Phelan, P. Ghadirian, H.T. Lynch, J. Garber, B. Weber, N. Tung, D. Horsman, C. Isaacs, A.N. Monteiro, P. Sun, and S.A. Narod Cancer variation associated with the position of the mutation in the BRCA2 gene Fam Cancer 3 2004 1 10 (Pubitemid 40655347)
15. B. Kremeyer, M. Soller, K. Lagerstedt, P. Maguire, S. Mazoyer, M. Nordling, J. Wahlström, and A. Lindblom The BRCA1 exon 13 duplication in the Swedish population Fam Cancer 4 2 2005 191 194 (Pubitemid 40897823)
16. B. Modan, P. Hartge, G. Hirsh-Yechezkel, A. Chetrit, F. Lubin, U. Beller, G. Ben-Baruch, A. Fishman, J. Menczer, S.M. Ebbers, M.A. Tucker, and S. Wacholder Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation N. Engl. J. Med. 345 4 2001 Jul 26 235 240 (Pubitemid 32695062)
17. A. Liede, I.A. Malik, Z. Aziz, P. de los Rios, E. Kwan, and S.A. Narod Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan Am. J. Hum. Genet. 71 2002 595 606 (Pubitemid 34970130)
18. J. Boyd, Y. Sonoda, M.G. Federici, F. Bogomolniy, E. Rhei, D.L. Maresco, P.E. Saigo, L.A. Almadrones, R.R. Barakat, C.L. Brown, D.S. Chi, and J.P. Curtin Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 17 2000 May 3 2260 2265 (Pubitemid 30246777)
19. K.A. Metcalfe, I. Fan, J. McLaughlin, H.A. Risch, B. Rosen, J. Murphy, L. Bradley, S. Armel, P. Sun, and S.A. Narod Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study Gynecol. Oncol. 112 1 2009 Jan 68 72
20. A. Finch, M. Beiner, J. Lubinski, H.T. Lynch, P. Moller, B. Rosen, J. Murphy, P. Ghadirian, E. Friedman, W.D. Foulkes, C. Kim-Sing, and T. Wagner Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation 2 JAMA 296 2006 Jul 12 185 192
21. S.A. Narod, H. Risch, R. Moslehi, A. Dørum, S. Neuhausen, H. Olsson, D. Provencher, P. Radice, G. Evans, S. Bishop, J.S. Brunet, and B.A. Ponder Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group N. Engl. J. Med. 339 7 1998 Aug 13 424 428 (Pubitemid 28377683)
22. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 2003 2187 2195 (Pubitemid 36444059)
23. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S.B. Kaye, and M.E. Gore BRCAness″ syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J. Clin. Oncol. 26 34 2008 Dec 1 5530 5536
24. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, and J. Carmichael Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134